
The AGILE and FORWARD studies found comparable efficacy and safety with shorter doses and higher dose, monthly doses, compared to the pivotal MIRROR trial.

The AGILE and FORWARD studies found comparable efficacy and safety with shorter doses and higher dose, monthly doses, compared to the pivotal MIRROR trial.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

Published: December 4th 2024 | Updated:

Published: July 17th 2025 | Updated: